The Pharma Data

MARCH 3, 2022

The FDA decision is informed by the results of the Phase 2b proof-of-concept study of RSVpreF (NCT04032093), a global, double-blinded, placebo-controlled study that assessed the safety and immunogenicity of RSVpreF in healthy pregnant women ages 18 through 49 years old, who were vaccinated between 28- and 36-weeks gestation, and their infants.

Virus 52

Virus Vaccine Clinical Trials Trials 52

The Pharma Data

NOVEMBER 16, 2020

16, 2020 — Scientists are reporting early success with an experimental herpes vaccine that uses a genetically modified version of the virus. The gene edit prevents the virus from performing its normal evasive maneuver: hiding out in nervous system cells in order to elude the immune system. MONDAY, Nov.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

BMG Labtech

MARCH 11, 2024

biomarker discovery), blood typing, autoimmune diseases, food science (including allergy testing), infectious disease surveillance, drug discovery and development as well as vaccine development. ELISAs can also be used to measure the antibody responses elicited by vaccines.

Vaccine 98

Vaccine Molecular Biology Laboratories Virus 98

DrugBaron

APRIL 13, 2020

More than a month after the World Health Organisation declared COVID19 a global pandemic on 11th March we are still missing one crucial piece of data from our modelling: the fraction of people who have established productive immunity against the SARS-CoV2 virus.

Immune Response 100

Immune Response Virus Vaccine Production 100

Drug Target Review

DECEMBER 28, 2023

These newly formed mutated proteins are called neoantigens and they are only present on tumour cells and are not found in normal, healthy cells. Findings from a leading-edge study called TRACERx have demonstrated how mutations that occur very early in the process of cancer genesis remain present in all cells of a growing tumour.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

The Pharma Data

NOVEMBER 23, 2020

. Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine.

Vaccine 52

Vaccine Virus Trials Clinical Trials 52

Drug Target Review

JANUARY 15, 2024

An important limitation of antibodies against tumour antigens is that these agents direct responses to molecular targets present on the surface of the cell. Figure 1: HLA Class I presentation of peptides derived from intracellular antigens. As described below, it also presents challenges and opportunities for TCR-based therapeutics.

Engineering 110

Engineering DNA Virus Immune Response 110

The Pharma Data

JULY 6, 2021

If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, pieces scientists call epitopes. These epitopes could then be used in a vaccine to train T cells, providing protective immunity.

Vaccine 52

Vaccine Virus Research Immune Response 52

The Pharma Data

MARCH 25, 2021

European Medicines Agency to Conduct First-Ever Parallel Assessment of a Medicinal Product, Takeda’s Dengue Vaccine Candidate (TAK-003), for use in the EU; Countries Outside of the EU through the EU-M4all (Previously Article 58) Procedure.

Vaccine 52

Vaccine Virus Trials Hospitals 52

The Pharma Data

DECEMBER 16, 2020

Food and Drug Administration (FDA) advisory panel in regard to the COVID-19 vaccine from Moderna. The Vaccines and Related Biological Products Advisory Committee will be determining whether the product should be authorized for emergency use, according to CNBC. ET, according to a draft of the agenda.

Vaccine 52

Vaccine Immune Response FDA FDA Approval 52

The Pharma Data

JUNE 25, 2021

In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria. 37, first identified in Peru (21%) and B.1.621,

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

AUGUST 16, 2021

The study assessed cynomolgus macaques vaccinated with 12µg of either the first or second-generation vaccine candidate. During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

DECEMBER 10, 2020

–( BUSINESS WIRE )– ImmunityBio , a privately-held immunotherapy company, today announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates against coronavirus (SARS-CoV-2) in a challenge study. 11, 2020 02:48 UTC. CULVER CITY, Calif.–( This press release features multimedia.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

JANUARY 5, 2021

Food and Drug Administration said Monday that any American who gets the Moderna or Pfizer coronavirus vaccines must get two full doses, despite international debate on possible ways to stretch vaccine supply. vaccine effort just as the public is starting to trust the program, Dr. . In the U.K., In the U.K.,

Vaccine 52

Vaccine FDA Virus Immune Response 52

Codon

DECEMBER 12, 2024

It’s important to note that the 300-page report, while presenting detailed evidence for the potential harms of mirrored life, uses painstakingly speculative language. A mirrored organism would use right-handed molecules everywhere a naturally-occurring organism uses left-handed ones, and vice versa. It gives humanity time to steer away.

RNA 104

RNA DNA Vaccine Virus 104

Agency IQ

MARCH 7, 2024

Vaccines advisory panel endorses move to trivalent formulation for U.S. flu vaccines Yesterday, FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) weighed in on strains for seasonal influenza vaccines for the Northern hemisphere 2024-2025 season.

Vaccine 40

Vaccine FDA Virus Licensing 40

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccine 52

Vaccine Immune Response Government RNA 52

Broad Institute

JANUARY 30, 2024

He has also emerged in recent years as a skilled and relatable science communicator, renowned for his efforts at Broad and beyond during the COVID-19 pandemic to unpack the fast-moving research on the new virus in an accessible way and give practical advice about masking, vaccines, and other public health measures.

Hospitals 137

Hospitals Virus Medical Schools Science 137

The Pharma Data

DECEMBER 18, 2020

Food and Drug Administration said Thursday night that it will move quickly to authorize the emergency use of Moderna’s coronavirus vaccine after one of its advisory panels voted to give its blessing to the shot. “Following today’s positive advisory committee meeting outcome regarding the Moderna COVID-19 vaccine, the U.S.

Vaccine 52

Vaccine FDA Government Hospitals 52

The Pharma Data

APRIL 26, 2022

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

The Pharma Data

DECEMBER 16, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 million doses of NVX-CoV2373, Novavax’ candidate vaccine against COVID-19. About NVX-CoV2373. About Novavax.

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

The Pharma Data

JANUARY 31, 2021

Gilead and Gritstone will develop an HIV-specific therapeutic vaccine using Gritstone’s proprietary prime-boost vaccine platform, comprised of self-amplifying mRNA (SAM) and adenoviral vectors, with antigens developed by Gilead. This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

JULY 21, 2021

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. at Month 7). Juan Carlos Jaramillo M.D., About VLA15.

Vaccine 52

Vaccine Disease Trials Protein Expression 52

Codon

AUGUST 27, 2024

” These are short sequences of DNA that are highly conserved, meaning they are likely to be present in a wide variety of sequences. While reading all the sequences present in a sample, researchers want to find any that are out of place, such as those that belong to a never-before-seen virus.

DNA 102

DNA Laboratories Hospitals Virus 102

Drug Target Review

JANUARY 3, 2024

Nanobodies are a novel and unique class of antigen-binding fragments, derived from naturally occurring heavy-chain-only antibodies present in the serum of camelids. 1 Acute gastroenteritis, a global health problem for which there are no vaccines or antiviral drugs, is caused by human noroviruses. Viruses in the GII.4 4 norovirus.

Virus 64

Virus Immune Response Vaccine Disease 64

Codon

APRIL 30, 2023

Also, last week’s digest had an error: The country that approved the malaria vaccine was Ghana. Vaccines (basically little fat bubbles filled with mRNA and some dissolvable polymers) were physically printed onto microneedle patches using a robot. The patches have little spikes that help push the vaccines through the skin.

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

APRIL 30, 2023

Also, last week’s digest had an error: The country that approved the malaria vaccine was Ghana. Vaccines (basically little fat bubbles filled with mRNA and some dissolvable polymers) were physically printed onto microneedle patches using a robot. The patches have little spikes that help push the vaccines through the skin.

Vaccine 52

Vaccine DNA Engineering RNA 52

The Pharma Data

DECEMBER 22, 2020

“The variant might already be present here and observed soon,” Lorenzo-Redondo said. ” Can a variant limit the effectiveness of the vaccine? “These mutations do not seem to impact vaccine efficacy, but they need to be fully characterized,” Lorenzo-Redondo said. and the U.K. .”

Virus 52

Virus Vaccine Immune Response Treatment 52

The Pharma Data

DECEMBER 25, 2020

While early data suggests that these new variants may be more transmissible, to date there is no evidence that they cause more severe disease or have any impact on antibody response or vaccine effectiveness. The best way to prevent infection with any variant of COVID-19 is to follow public health measures.

Virus 40

Virus Compliance Government Laboratories 40

The Pharma Data

APRIL 25, 2021

Nirsevimab demonstrate d protect ion against respiratory syncytial virus disease in healthy infants in Phase 3 trial. Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants. Results will be presented at an upcoming scientific congress and are anticipated to form the basis of regulatory submissions.

Virus 40

Virus Trials Disease Hospitals 40

NIH Director's Blog: Drug Development

JUNE 30, 2020

A major one is: just how well do those particular antibodies neutralize the virus to fight off the infection and help someone recover from COVID-19? In the Nussenzweig lab, the team has spent years searching for broadly neutralizing antibodies against the human immunodeficiency virus (HIV ). Yet many critical questions remain.

Immune Response 52

Immune Response Virus Vaccine Research 52

The Pharma Data

AUGUST 22, 2020

Coronavirus will be present “forever in some form or another”, a member of the government’s Scientific Advisory Group for Emergencies (Sage) has said. Sir Mark Walport said people would need to be vaccinated at regular intervals. Sir Mark said denser populations and travel meant the virus spread easily.

Vaccine 52

Vaccine Virus Government Disease 52

The Pharma Data

DECEMBER 8, 2020

8 December 2020 — Results of an interim analysis of the Phase III programme conducted by Oxford University with AZD1222, peer-reviewed and published in The Lancet today, demonstrated that the vaccine is safe and effective at preventing symptomatic COVID-19 and that it protects against severe disease and hospitalisation.

Trials 52

Trials Vaccine Virus Disease 52

The Pharma Data

FEBRUARY 12, 2022

The COVID-causing virus SARS-CoV-2 harbors a vulnerable site at the base of its spike protein that is found also on closely related coronaviruses, according to a new study from Scripps Research. That prospect has spurred efforts towards the development of a pan-beta-coronaviral vaccine or antibody therapy.

Virus 52

Virus Vaccine Therapies Research 52

The Pharma Data

JUNE 29, 2021

Professor Sir Andrew J Pollard, chief investigator and director of the Oxford Vaccine Group at the University of Oxford, said: “This should come as reassuring news to countries with lower supplies of the vaccine, who may be concerned about delays in providing second doses to their populations. Vaxzevria , formerly AZD1222.

Immune Response 52

Immune Response Vaccine Virus Trials 52

The Pharma Data

JUNE 25, 2021

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% “Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines. Glenn, M.D.,

Vaccine 40

Vaccine Trials Disease Immune Response 40

The Pharma Data

NOVEMBER 29, 2021

1.1.529 a variant of concern, named Omicron, on the advice of WHO’s Technical Advisory Group on Virus Evolution (TAG-VE). Effectiveness of vaccines : WHO is working with technical partners to understand the potential impact of this variant on our existing countermeasures, including vaccines. Studies underway.

Vaccine 52

Vaccine Virus Disease Hospitals 52